通化金马：研制的化学1类新药琥珀八氢氨吖啶片主要用于治疗轻中度阿尔茨海默病

Core Viewpoint - Tonghua Jinma (000766) is advancing its research on a new chemical drug, Amber Dihydroaminoacridine Tablets, aimed at treating mild to moderate Alzheimer's disease, with the review process currently in the comprehensive evaluation stage [1] Group 1 - The new drug has completed all professional review work and is now in the comprehensive evaluation phase [1] - The company will disclose any information that meets the disclosure standards as per relevant regulations [1]